Preferred Label : Valsartan;
Obsolete resource : false;
MeSH definition : A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to
treat HYPERTENSION.;
MeSH synonym : N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine;
MeSH hyponym : CGP 48933; kalpress; provas; nisis; miten; diovan; Tareg; vals; 48933, CGP;
MeSH CAS label : L-Valine, N-(1-oxopentyl)-N-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-;
MeSH Related Number : 137862-53-4;
Wikipedia link : https://en.wikipedia.org/wiki/Valsartan;
Is substance : O;
UNII : 80M03YXJ7I;
Origin ID : D000068756;
UMLS CUI : C0216784;
ATC code(s)
ATC code(s)
Allowable qualifiers
CISMeF manual mappings
False automatic mappings
Pharmacological action(s)
Record concept(s)
Related MeSH Supplementary Concept(s)
See also
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to
treat HYPERTENSION.
https://www.has-sante.fr/jcms/p_3286131/fr/sam-de-la-has-sur-le-tareg-valsartan-3-mg/ml-solution-buvable-alerter-sur-le-risque-d-erreur-de-dose-lie-au-dispositif-d-administration
2021
false
false
false
France
drug information
algorithms
clinical tool
operations research
solutions
mosaicism
chromosome disorders
mosaic variegated aneuploidy syndrome
Tareg
administration
Solutions
indexing
Set, Psychology
operations research
macrophage activation syndrome
risk
drug, nos
solutions
devices
equipment and supplies
Abstracting and Indexing
Valsartan
organization and administration
Administration
pharmaceutical preparations
decision support techniques
device, nos
meconium aspiration syndrome
solution, nos
---
https://www.has-sante.fr/jcms/p_3182805
2020
France
evaluation of the transparency committee
Tareg
Valsartan
---
https://www.ansm.sante.fr/actualites/conduite-a-tenir-dans-un-contexte-de-tensions-dapprovisionnement-des-medicaments-a-base-de-valsartan
2018
false
false
false
France
French
Valsartan
pharmacovigilance note
hypertension
heart failure
myocardial infarction
Valsartan
antihypertensive agents
antihypertensive agents
---
https://pharmacomedicale.org/medicaments/par-specialites/item/traitements-de-l-anemie-les-points-essentiels-2
2018
false
true
false
France
neprilysin
angiotensin II receptor antagonists
sacubitril and valsartan sodium hydrate drug combination
sacubitril and valsartan sodium hydrate drug combination
sacubitril and valsartan sodium hydrate drug combination
valsartan and sacubitril
heart failure
sacubitril
Valsartan
drug information
angiotensin receptor antagonists
sacubitril and valsartan sodium hydrate drug combination
sacubitril and valsartan sodium hydrate drug combination
sacubitril and valsartan sodium hydrate drug combination
aminobutyrates
tetrazoles
aminobutyrates
tetrazoles
aminobutyrates
tetrazoles
---
https://pharmactuel.com/index.php/pharmactuel/article/view/1233
2018
false
false
false
Canada
sacubitril and valsartan sodium hydrate drug combination
sacubitril and valsartan sodium hydrate drug combination
angiotensin receptor antagonists
heart failure
Valsartan
heart failure
treatment outcome
quality of life
hypotension
hospitalization
neprilysin
journal article
aminobutyrates
tetrazoles
---
https://ansm.sante.fr/actualites/Nouveau-rappel-de-medicaments-a-base-de-valsartan-Informations-pour-les-patients-et-les-professionnels-de-sante
2018
false
false
false
false
France
French
guidelines for drug use
Valsartan
Valsartan
drug combinations
hydrochlorothiazide
administration, oral
drug contamination
patients guideline
valsartan
valsartan and diuretics
Safety-Based drug withdrawals
---
https://ansm.sante.fr/informations-de-securite/valsartan-quels-sont-les-patients-prioritaires-dans-un-contexte-dintenses-tensions-dapprovisionnement
2018
false
false
false
France
French
guidelines for drug use
Valsartan
heart failure
hypertension
myocardial infarction
Valsartan
antihypertensive agents
antihypertensive agents
administration, oral
---
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2018/68448a-fra.php
2018
false
false
false
France
French
Valsartan
pharmacovigilance note
Safety-Based drug withdrawals
drug contamination
drugs, generic
canada
---
Health Canada advises of a second impurity linked to recalled valsartan drugs
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2018/67746a-fra.php
2018
false
false
false
Canada
French
English
drug contamination
drugs, generic
canada
Valsartan
diethylnitrosamine
neoplasms
---
https://ansm.sante.fr/informations-de-securite/mesures-a-lattention-des-medecins-et-pharmaciens-dans-le-cadre-du-rappel-de-certaines-specialites-a-base-de-valsartan-et-de-valsartan-hydrochlorothiazide
2018
false
false
false
France
French
pharmacovigilance note
Valsartan
Safety-Based drug withdrawals
valsartan and diuretics
valsartan
administration, oral
hypertension
heart failure
drugs, generic
drug contamination
---
https://www.ansm.sante.fr/actualites/rappel-de-certains-medicaments-a-base-de-valsartan-lansm-met-a-disposition-des-patients-un-numero-vert-et-un-document-dinformation
2018
false
false
false
France
French
pharmacovigilance note
Valsartan
Safety-Based drug withdrawals
valsartan and diuretics
valsartan
administration, oral
hypertension
heart failure
drugs, generic
drug contamination
patient education handout
hotlines
antihypertensive agents
Valsartan
drug combinations
Product containing hydrochlorothiazide and valsartan (medicinal product)
---
Teva Canada expands recall of valsartan drugs to include additional lots, as a precaution
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2018/67552a-fra.php
2018
false
false
false
Canada
French
English
drugs, generic
Valsartan
pharmacovigilance note
Safety-Based drug withdrawals
drug contamination
canada
---
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2018/67734a-fra.php
2018
false
false
false
false
France
French
patient education handout
drug information
drug recalls
Communication
Valsartan
risk assessment
Communication
Communications; transports; civil engineering
hazardous substances
recent
common
canada
risk
drug, nos
Municipality
appraiser
health communication
risk
Valsartan
antihypertensive agents
---
http://www.has-sante.fr/portail/jcms/c_2632556/fr/entresto
2017
false
false
false
France
French
sacubitril and valsartan sodium hydrate drug combination
neprilysin
angiotensin receptor antagonists
drug combinations
adult
heart failure
administration, oral
sacubitril and valsartan sodium hydrate drug combination
treatment outcome
valsartan and sacubitril
Valsartan
Valsartan
evaluation of the transparency committee
chronic disease
insurance, health, reimbursement
Reduced ejection fraction
chronic heart failure
angiotensin receptor antagonists
aminobutyrates
aminobutyrates
tetrazoles
tetrazoles
---
http://www.has-sante.fr/portail/jcms/c_2626273/fr/cotareg
http://www.has-sante.fr/portail/jcms/c_1036309/cotareg
http://www.has-sante.fr/portail/jcms/c_455314/fr/cotareg
2016
false
France
French
Valsartan
hypertension
angiotensin II type 1 receptor blockers
insurance, health, reimbursement
valsartan and diuretics
hydrochlorothiazide
diuretics
drug combinations
administration, oral
antihypertensive agents
sodium chloride symporter inhibitors
treatment outcome
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/jcms/c_2658603/fr/nisis
http://www.has-sante.fr/portail/jcms/c_1046805/nisis
2016
false
France
French
Valsartan
-
-
-
administration, oral
angiotensin II type 1 receptor blockers
antihypertensive agents
valsartan
hypertension
myocardial infarction
heart failure
treatment outcome
insurance, health, reimbursement
evaluation of the transparency committee
---
https://www.ema.europa.eu/medicines/human/EPAR/Neparvis
2016
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Valsartan
drug approval
europe
treatment outcome
sacubitril and valsartan sodium hydrate drug combination
sacubitril and valsartan sodium hydrate drug combination
valsartan and sacubitril
drug combinations
product surveillance, postmarketing
adult
chronic heart failure
administration, oral
angiotensin receptor antagonists
angiotensin receptor antagonists
neprilysin
drug interactions
pregnancy
breast feeding
prodrugs
drug evaluation, preclinical
Valsartan
sacubitril and valsartan sodium hydrate drug combination
sacubitril and valsartan sodium hydrate drug combination
aminobutyrates
tetrazoles
aminobutyrates
tetrazoles
---
http://www.has-sante.fr/portail/jcms/c_2626282/fr/tareg
2016
false
France
French
Valsartan
hypertension
adult
child
adolescent
Postinfarction
administration, oral
antihypertensive agents
angiotensin II type 1 receptor blockers
insurance, health, reimbursement
-
-
-
valsartan
heart failure
treatment outcome
evaluation of the transparency committee
---
Summary Basis of Decision (SBD) for Entresto
Sacubitril/valsartan (as sacubitril valsartan sodium hydrate complex) 24.3 mg sacubitril/25.7
mg valsartan 48.6 mg sacubitril/51.4 mg valsartan 97.2 mg sacubitril/102.8 mg valsartan
Tablets, oral
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?linkID=SBD00208
2015
false
false
false
Canada
French
English
summary of product characteristics
sacubitril and valsartan sodium hydrate drug combination
neprilysin
angiotensin receptor antagonists
drug combinations
adult
heart failure, systolic
administration, oral
sacubitril and valsartan sodium hydrate drug combination
product surveillance, postmarketing
drug evaluation, preclinical
treatment outcome
valsartan and sacubitril
drug approval
canada
Valsartan
Valsartan
aminobutyrates
aminobutyrates
---
https://www.ema.europa.eu/medicines/human/EPAR/Entresto
2015
false
false
false
United Kingdom
French
English
summary of product characteristics
package leaflet
sacubitril and valsartan sodium hydrate drug combination
neprilysin
angiotensin receptor antagonists
drug combinations
adult
heart failure, systolic
administration, oral
syndication feed
drug evaluation
sacubitril and valsartan sodium hydrate drug combination
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
treatment outcome
valsartan and sacubitril
Valsartan
Valsartan
sacubitril
sacubitril
aminobutyrates
aminobutyrates
---
https://www.ema.europa.eu/medicines/human/EPAR/Dafiro-HCT
2012
false
United Kingdom
English
French
syndication feed
Valsartan
Valsartan
breast feeding
drug evaluation, preclinical
drug combinations
antihypertensive agents
amlodipine
calcium channel blockers
sodium chloride symporter inhibitors
diuretics
hydrochlorothiazide
antihypertensive agents
amlodipine
angiotensin II type 1 receptor blockers
angiotensin II type 1 receptor blockers
calcium channel blockers
sodium chloride symporter inhibitors
diuretics
hydrochlorothiazide
drug approval
drug labeling
treatment outcome
tablets
administration, oral
adult
aged
drug interactions
pregnancy
valsartan, amlodipine and hydrochlorothiazide
Amlodipine Besylate
Product containing amlodipine and hydrochlorothiazide and valsartan (medicinal product)
drug evaluation
summary of product characteristics
package leaflet
---
https://www.ema.europa.eu/medicines/human/EPAR/Exforge-HCT
2012
false
United Kingdom
French
English
syndication feed
Valsartan
Valsartan
drug labeling
treatment outcome
drug approval
administration, oral
adult
aged
diuretics
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
angiotensin II type 1 receptor blockers
amlodipine
antihypertensive agents
sodium chloride symporter inhibitors
hydrochlorothiazide
amlodipine
antihypertensive agents
sodium chloride symporter inhibitors
calcium channel blockers
diuretics
hydrochlorothiazide
angiotensin II type 1 receptor blockers
calcium channel blockers
drug combinations
valsartan, amlodipine and hydrochlorothiazide
exforge HCT
Amlodipine Besylate
summary of product characteristics
package leaflet
drug evaluation
---
https://www.ema.europa.eu/medicines/human/EPAR/Imprida-HCT
2012
false
United Kingdom
English
French
syndication feed
Valsartan
Valsartan
antihypertensive agents
amlodipine
calcium channel blockers
sodium chloride symporter inhibitors
diuretics
hydrochlorothiazide
antihypertensive agents
amlodipine
calcium channel blockers
sodium chloride symporter inhibitors
diuretics
hydrochlorothiazide
angiotensin II type 1 receptor blockers
angiotensin II type 1 receptor blockers
drug combinations
drug labeling
treatment outcome
tablets
administration, oral
adult
drug approval
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
valsartan, amlodipine and hydrochlorothiazide
Amlodipine Besylate
summary of product characteristics
drug evaluation
package leaflet
---
https://www.ema.europa.eu/medicines/human/EPAR/Copalia-HCT
2012
false
United Kingdom
English
French
syndication feed
Valsartan
Valsartan
antihypertensive agents
amlodipine
calcium channel blockers
sodium chloride symporter inhibitors
diuretics
hydrochlorothiazide
amlodipine
hydrochlorothiazide
antihypertensive agents
angiotensin II type 1 receptor blockers
angiotensin II type 1 receptor blockers
diuretics
calcium channel blockers
sodium chloride symporter inhibitors
tablets
administration, oral
adult
drug approval
drug labeling
treatment outcome
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
drug combinations
valsartan, amlodipine and hydrochlorothiazide
Amlodipine Besylate
Product containing amlodipine and hydrochlorothiazide and valsartan (medicinal product)
summary of product characteristics
drug evaluation
package leaflet
---
http://www.has-sante.fr/portail/jcms/c_944504/exforge-hct
http://www.has-sante.fr/portail/jcms/c_1250041/exforge-hct
2012
false
France
French
evaluation of the transparency committee
Valsartan
exforge HCT
drug combinations
administration, oral
insurance, health, reimbursement
hydrochlorothiazide
amlodipine
Amlodipine Besylate
valsartan, amlodipine and hydrochlorothiazide
hypertension
adult
aged
treatment outcome
clinical trials, phase iii as topic
antihypertensive agents
---
http://www.has-sante.fr/portail/jcms/c_1294042/exforge-hct-synthese-28032012
http://www.has-sante.fr/portail/jcms/c_1251529/exforge-hct-28032012-avis-ct11985
http://www.has-sante.fr/portail/jcms/c_1294106/exforge-hct-association-fixe-amlodipine/valsartan/hydrochlorothiazide
2012
false
France
French
evaluation of the transparency committee
guidelines for drug use
Valsartan
antihypertensive agents
diuretics
hypertension
valsartan, amlodipine and hydrochlorothiazide
Amlodipine Besylate
adult
aged
randomized controlled trials as topic
diastolic pressure
systolic pressure
blood pressure
hydrochlorothiazide
exforge HCT
drug combinations
administration, oral
insurance, health, reimbursement
treatment outcome
amlodipine
comparative study
---
http://www.has-sante.fr/portail/jcms/c_1046778/tareg-solution-buvable
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-04/tareg_solution_buvable_-_ct_-9679.pdf
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-11/tareg_ct_9679.pdf
2011
false
France
French
English
Valsartan
-
administration, oral
pharmaceutical solutions
angiotensin II type 1 receptor blockers
antihypertensive agents
valsartan
insurance, health, reimbursement
child
adolescent
hypertension
treatment outcome
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/jcms/c_1062869/tareg-valsartan-antagoniste-des-recepteurs-de-langiotensine-ii-synthese-d-avis
2011
false
France
French
evaluation of the transparency committee
guidelines for drug use
Valsartan
-
-
-
-
administration, oral
tablets
pharmaceutical solutions
valsartan
child
insurance, health, reimbursement
angiotensin II type 1 receptor blockers
antihypertensive agents
hypertension
adolescent
treatment outcome
---
http://www.has-sante.fr/portail/jcms/c_1046796/tareg
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-04/tareg_pediatrie-_ct-_9680.pdf
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-11/tareg_ct_9680.pdf
2011
false
France
French
English
Valsartan
tablets
administration, oral
angiotensin II type 1 receptor blockers
antihypertensive agents
valsartan
-
-
child
adolescent
hypertension
insurance, health, reimbursement
treatment outcome
risk assessment
-
evaluation of the transparency committee
---
http://www.lecrat.eu/?s=Valsartan+-+NISIS%C2%AE%2C+TAREG%C2%AE
2011
false
France
French
Valsartan
pregnancy
teratogens
angiotensin II type 1 receptor blockers
antihypertensive agents
scientific and technical information
---
http://www.has-sante.fr/portail/jcms/c_999460/nisis-ct-9032
http://www.has-sante.fr/portail/jcms/c_997086/tareg-ct-9030
http://www.has-sante.fr/portail/jcms/c_1020466/nisis-tareg-valsartan-antagoniste-des-recepteurs-de-langiotensine-ii
http://www.has-sante.fr/portail/jcms/c_1020440/synthese-d-avis-nisis-tareg-ct-9030-9032
2010
false
France
French
Valsartan
-
-
-
-
-
-
administration, oral
angiotensin II type 1 receptor blockers
heart failure
valsartan
evaluation of the transparency committee
guidelines for drug use
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-04/exforge_hct-_ct-7151.pdf
http://www.has-sante.fr/portail/jcms/c_966568/exforge-hct-association-fixe-damlodipine/valsartan/hydrochlorothiazide-antihypertenseur
2010
false
France
French
Valsartan
drug combinations
amlodipine
hydrochlorothiazide
administration, oral
insurance, health, reimbursement
valsartan, amlodipine and hydrochlorothiazide
hypertension
adult
treatment outcome
antihypertensive agents
exforge HCT
Amlodipine Besylate
evaluation of the transparency committee
guidelines for drug use
---
http://www.has-sante.fr/portail/jcms/c_997503/tareg
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-11/tareg_-_ct-8529.pdf
2010
false
France
French
Valsartan
guidelines for drug use
administration, oral
antihypertensive agents
angiotensin II type 1 receptor blockers
valsartan
insurance, health, reimbursement
-
-
-
heart failure
ventricular dysfunction, left
myocardial infarction
treatment outcome
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-11/nisis_-_ct-9032.pdf
http://www.has-sante.fr/portail/jcms/c_999443/nisis
2010
false
France
French
Valsartan
valsartan
administration, oral
-
-
-
antihypertensive agents
angiotensin II type 1 receptor blockers
heart failure
treatment outcome
insurance, health, reimbursement
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-11/nisis_-_ct-8991.pdf
http://www.has-sante.fr/portail/jcms/c_997504/nisis
http://www.has-sante.fr/portail/jcms/c_1020442/synthese-nisis-tareg-ct-8991-8529
http://www.has-sante.fr/portail/jcms/c_999100/tareg-ct-8529
2010
false
France
French
Valsartan
antihypertensive agents
angiotensin II type 1 receptor blockers
administration, oral
-
-
-
valsartan
insurance, health, reimbursement
heart failure
ventricular dysfunction, left
myocardial infarction
treatment outcome
-
-
-
evaluation of the transparency committee
guidelines for drug use
---
http://www.has-sante.fr/portail/display.jsp?id=c_456403
http://www.has-sante.fr/portail/upload/docs/application/pdf/ct-2894_nisisco.pdf
2006
false
France
French
Valsartan
hydrochlorothiazide
drug combinations
angiotensin II type 1 receptor blockers
antihypertensive agents
valsartan and diuretics
diuretics
insurance, health, reimbursement
administration, oral
hypertension
evaluation of the transparency committee
---
https://minerva-ebp.be/fr/article/724
2006
false
false
minerva-ebm.be
Belgium
French
Valsartan
Valsartan
hypertension
amlodipine
amlodipine
antihypertensive agents
antihypertensive agents
calcium channel blockers
calcium channel blockers
cardiovascular diseases
treatment outcome
angiotensin II type 1 receptor blockers
Amlodipine Besylate
critical appraisal or critical reading
comparative study
---